Clinical trial · Interventional
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects
NCT00328770CI-TRIAL-00010986completedPhase 2 / Phase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Carcinoma | Liver Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sirolimus | Drug | Sirolimus | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sirolimus based immunosuppression
- description
- Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
- interventionNames
- Drug: Sirolimus
Primary outcomes (2)
- measure
- Percentage of Participants Surviving at One and Four Years After Liver Transplant
- timeFrame
- 1 & 4 years
- description
- Percent of Patients Surviving at One \& Four years after Liver Transplant was calculated
- measure
- Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant
- timeFrame
- 1 and 4 years
- description
- Percentage of Participants Surviving with no Evidence of Recurrent Hepatocellular Carcinoma at One and Four Years After Liver Transplant
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant Exclusion criteria: * Patients less than 18 years of age
References
Publications (1)
- DERIVEDTreiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247. PMID 19192962